Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Rocket Pharmaceuticals (RCKT) Invested Capital (2016 - 2025)

Historic Invested Capital for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Q3 2025 value amounting to $313.7 million.

  • Rocket Pharmaceuticals' Invested Capital fell 488.28% to $313.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $313.7 million, marking a year-over-year decrease of 488.28%. This contributed to the annual value of $463.2 million for FY2024, which is 595.65% down from last year.
  • According to the latest figures from Q3 2025, Rocket Pharmaceuticals' Invested Capital is $313.7 million, which was down 488.28% from $354.2 million recorded in Q2 2025.
  • Rocket Pharmaceuticals' 5-year Invested Capital high stood at $541.1 million for Q3 2023, and its period low was $313.7 million during Q3 2025.
  • Moreover, its 5-year median value for Invested Capital was $441.5 million (2024), whereas its average is $429.8 million.
  • Per our database at Business Quant, Rocket Pharmaceuticals' Invested Capital surged by 10081.71% in 2021 and then tumbled by 3905.39% in 2024.
  • Rocket Pharmaceuticals' Invested Capital (Quarter) stood at $454.7 million in 2021, then rose by 7.69% to $489.7 million in 2022, then rose by 0.59% to $492.6 million in 2023, then dropped by 5.96% to $463.2 million in 2024, then plummeted by 32.29% to $313.7 million in 2025.
  • Its Invested Capital stands at $313.7 million for Q3 2025, versus $354.2 million for Q2 2025 and $412.1 million for Q1 2025.